Sun Pharm Inds Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SUN PHARM INDS, and when can generic versions of SUN PHARM INDS drugs launch?
SUN PHARM INDS has two hundred and twenty-one approved drugs.
There are two US patents protecting SUN PHARM INDS drugs. There are eleven tentative approvals on SUN PHARM INDS drugs.
There are three patent family members on SUN PHARM INDS drugs in three countries and two hundred and ten supplementary protection certificates in sixteen countries.
Summary for Sun Pharm Inds
| International Patents: | 3 |
| US Patents: | 2 |
| Tradenames: | 165 |
| Ingredients: | 156 |
| NDAs: | 221 |
Drugs and US Patents for Sun Pharm Inds
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharm Inds | OXCARBAZEPINE | oxcarbazepine | TABLET;ORAL | 077794-003 | Oct 9, 2007 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Sun Pharm Inds Ltd | CARVEDILOL | carvedilol | TABLET;ORAL | 076989-002 | Sep 5, 2007 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Sun Pharm Inds | ONDANSETRON | ondansetron | TABLET, ORALLY DISINTEGRATING;ORAL | 077557-002 | Aug 2, 2007 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Sun Pharm Inds Ltd | RANITIDINE HYDROCHLORIDE | ranitidine hydrochloride | TABLET;ORAL | 075439-001 | Apr 19, 2000 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Sun Pharm Inds | OCTREOTIDE ACETATE | octreotide acetate | INJECTABLE;INJECTION | 077329-002 | Mar 4, 2008 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Sun Pharm Inds
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Sun Pharm Inds Inc | ABSORICA | isotretinoin | CAPSULE;ORAL | 021951-005 | Aug 15, 2014 | 7,435,427 | ⤷ Try a Trial |
| Sun Pharm Inds Inc | ABSORICA | isotretinoin | CAPSULE;ORAL | 021951-003 | May 25, 2012 | 8,952,064 | ⤷ Try a Trial |
| Sun Pharm Inds Inc | ABSORICA | isotretinoin | CAPSULE;ORAL | 021951-005 | Aug 15, 2014 | 8,367,102 | ⤷ Try a Trial |
| Sun Pharm Inds Inc | ABSORICA | isotretinoin | CAPSULE;ORAL | 021951-004 | May 25, 2012 | 9,089,534 | ⤷ Try a Trial |
| Sun Pharm Inds Inc | ABSORICA | isotretinoin | CAPSULE;ORAL | 021951-003 | May 25, 2012 | 7,435,427 | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for SUN PHARM INDS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Capsules | 25 mg | ➤ Subscribe | 2016-05-16 |
| ➤ Subscribe | Capsules | 20 mg | ➤ Subscribe | 2013-01-07 |
| ➤ Subscribe | Capsules | 35 mg | ➤ Subscribe | 2015-11-25 |
| ➤ Subscribe | Capsules | 30 mg and 40 mg | ➤ Subscribe | 2012-12-31 |
| ➤ Subscribe | Capsules | 20 mg | ➤ Subscribe | 2013-06-19 |
International Patents for Sun Pharm Inds Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 3346996 | ⤷ Try a Trial |
| Japan | 2018530535 | ⤷ Try a Trial |
| World Intellectual Property Organization (WIPO) | 2017042835 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Sun Pharm Inds Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1412357 | SPC/GB08/040 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: SITAGLIPTIN OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR THE MONOPHOSPHATE, PLUS METFORMIN OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR THE HYDROCHLORIDE.; REGISTERED: CH 58450 01-03 20080408; UK EU/1/08/455/001 20080716; UK EU/1/08/455/002 20080716; UK EU/1/08/455/003 20080716; UK EU/1/08/455/004 20080716; UK EU/1/08/455/005 20080716; UK EU/1/08/455/006 20080716; UK EU/1/08/455/007 20080716; UK EU/1/08/455/008 20080716; UK EU/1/08/455/009 20080716; UK EU/1/08/455/010 20080716; UK EU/1/08/455/011 20080716; UK EU/1/08/455/012 20080716; UK EU/1/08/455/013 20080716; UK EU/1/08/455/014 20080716 |
| 0303507 | 64/1997 | Austria | ⤷ Try a Trial | PRODUCT NAME: ''NARATRIPTAN'', GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES ODER SOLVATES EINSCHLIESSLICH DES HYDROCHLORIDS; NAT. REGISTRATION NO/DATE: 1-22059 19970731; FIRST REGISTRATION: SE 13382 19970310 |
| 0247633 | 97C0118 | France | ⤷ Try a Trial | PRODUCT NAME: ATORVASTATINE CALCIQUE TRIHYDRATE; REGISTRATION NO/DATE IN FRANCE: NL 21960 DU 19970321; REGISTRATION NO/DATE AT EEC: PL 00018/0240 DU 19961107 |
| 1507558 | 2012/018 | Ireland | ⤷ Try a Trial | PRODUCT NAME: ALISKIREN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AMLODIPINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND HYDROCHLOROTHIAZIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; NAT REGISTRATION NO/DATE: EU/1/11/730/001-060 20111122; FIRST REGISTRATION NO/DATE: SWITZERLAND 6167801-6167805 20110705 |
| 0984957 | 122012000051 | Germany | ⤷ Try a Trial | PRODUCT NAME: KOMBINATIONSPRODUKT UMFASSEND NAPROXEN UND ESOMEPRAZOL-MAGNESIUM-TRIHYDRAT; NAT. REGISTRATION NO/DATE: 85145.00.00 20120202; FIRST REGISTRATION: GROSSBRITANNIEN PL 17901/0263 - 0001 20101105 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
